title: Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel.
abstract: 1. On the basis of their structure, we compared the ability of 35 xanthine derivatives to activate the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel stably expressed in chinese hamster ovary (CHO) cells using the cell-attached patch clamp and iodide efflux techniques. 2. Activation of CFTR channels was obtained with 3-mono, 1,3-di or 1,3,7-tri-substituted alkyl xanthine derivatives (enprofylline, theophylline, aminophylline, IBMX, DPMX and pentoxifylline). By contrast, xanthine derivatives substituted at the C8- or N9-position failed to open CFTR channels. 3. The CFTR chloride channel activity was blocked by glibenclamide (100 microM) but not by DIDS (100 microM). 4. Activation of CFTR by xanthines was not mimicked by the calcium ionophore A23187, adenosine, UTP, ATP or the specific phosphodiesterase inhibitors rolipram, Ro 20-1724 and milrinone. In addition, we found no correlation between the effect of xanthines on CFTR and on the cellular cyclic AMP or ATP levels. 5. We then synthesized a series of 3,7-dimethyl-1-alkyl xanthine derivatives; among them, 3,7-dimethyl-1-propyl xanthine and 3,7-dimethyl-1-isobutyl xanthine both activated CFTR channels without increasing the intracellular cyclic AMP level, while the structurally related 3,7-dimethyl-1-(2-propenyl) xanthine and 3,7-dimethyl-1-(oxiranyl methyl) xanthine were inactive. 6. Our findings delineate a novel function for xanthine compounds and identify the molecular features that enable xanthine activation of CFTR. These results may be useful in the development of new molecules for studying the pharmacology of chloride channels.
authors.affiliation: Laboratoire de Neurobiologie, CNRS, Marseille, France.
authors.forename: V
authors.initials: V
authors.lastname: Chappe
authors.forename: Y
authors.initials: Y
authors.lastname: Mettey
authors.forename: J M
authors.initials: JM
authors.lastname: Vierfond
authors.forename: J W
authors.initials: JW
authors.lastname: Hanrahan
authors.forename: M
authors.initials: M
authors.lastname: Gola
authors.forename: B
authors.initials: B
authors.lastname: Verrier
authors.forename: F
authors.initials: F
authors.lastname: Becq
mesh_terms: D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid / Q000494:pharmacology; D000818:Animals; D016466:CHO Cells; D005576:Colforsin / Q000494:pharmacology; D006224:Cricetinae; D000242:Cyclic AMP / Q000378:metabolism; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000819:agonists* / Q000037:antagonists & inhibitors; D005905:Glyburide / Q000494:pharmacology; D007454:Iodides / Q000378:metabolism; D017136:Ion Transport; D018408:Patch-Clamp Techniques; D011994:Recombinant Proteins / Q000819:agonists; D013329:Structure-Activity Relationship; D014970:Xanthines / Q000737:chemistry / Q000494:pharmacology*
chemical_list: D007454:Iodides; D011994:Recombinant Proteins; D014970:Xanthines; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D005576:Colforsin; D000242:Cyclic AMP; D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; D005905:Glyburide